These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1333 related articles for article (PubMed ID: 35435206)

  • 21. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
    BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
    Oğuz SH; Ünlütürk U; Aksoy S; Erbas T
    Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 24. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report.
    Iesaka H; Kameda H; Miya A; Nomoto H; Cho KY; Nakamura A; Abe T; Shinohara N; Atsumi T
    Medicine (Baltimore); 2023 Dec; 102(51):e36664. PubMed ID: 38134115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.
    Yin J; Wu Y; Yang X; Gan L; Xue J
    Front Immunol; 2022; 13():830631. PubMed ID: 35464480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 28. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.
    Lopez AT; Geskin L
    Oncologist; 2018 Oct; 23(10):1119-1126. PubMed ID: 30018132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
    Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
    Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report.
    Wei T; Wang Z; Liu X
    Medicine (Baltimore); 2023 Feb; 102(7):e32731. PubMed ID: 36800626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
    Takeno A; Yamamoto M; Morita M; Tanaka S; Kanazawa I; Yamauchi M; Kaneko S; Sugimoto T
    BMC Endocr Disord; 2019 Feb; 19(1):25. PubMed ID: 30782163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hyponatremia caused by pituitary metastasis of lung cancer].
    Uryu K; Umakoshi T; Hyakutake T; Willard YI; Yamashita K; Harada H
    Nihon Kokyuki Gakkai Zasshi; 2011 May; 49(5):371-6. PubMed ID: 21688646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors.
    Yoon JH; Hong AR; Kim HK; Kang HC
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):413-423. PubMed ID: 33820396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
    Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
    Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias.
    Yu Y; Chen N; Yu S; Shen W; Zhai W; Li H; Fan Y
    Cancer Res Treat; 2024 Jul; 56(3):751-764. PubMed ID: 38186241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    Luo W; Wang Z; Tian P; Li W
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.